The Group

The Tzamal Mission

To improve the quality of healthcare in Israel by providing the best medical products, medical devices and pharmaceuticals for treating patients
To improve the service provided to health institutions and doctors through optimal market exposure, backed by a high standard of logistical and operational support
To provide medical practitioners with the latest developments in medical technologies
To provide our partners and clients with the advantages of the Tzamal reputation, know-how and network of contacts, built over 35 years of success
To apply our in-depth knowledge of the “Economics of Healthcare” in order to provide the most cost-effective products whilst emphasizing long-term quality of life
To address new market opportunities by offering innovative products in fields not previously serviced by Tzamal

The Tzamal Advantage

Applying outstanding marketing expertise, encompassing intimate understanding of pre-marketing parameters, knowledge of market needs and future trends, to introduce new technologies and pharmaceutical products
Extensive experience and understanding of working with multi-national healthcare industry leaders
Leading in optimization of “Economics of Healthcare”, facilitating successful and economic integration of the latest medical innovations into the market
Team of 40 exceptional employees applying Tzamal marketing expertise to service our client needs
In-depth understanding of and compliance with international regulatory and quality requirements
Continual focus on partnering with new companies and manufacturers offering state-of-the-art innovative and market-viable technologies, for the benefits of our clients
On-going enrichment and expansion of our extensive knowledge base, for the benefit of our partners and clients

Tzamal Milestones

Established in 1972, Tzamal Medical Industries quickly found its market niche as exclusive Israeli representative to Johnson & Johnson, Ohmeda (B&D) and Schneider (Pfizer). Tzamal provided these companies with a significant penetration point, setting them up to eventually establish their own agencies in Israel and continue on to realize lucrative profits.

Between 1996 and 1998, Tzamal transferred its main operations to global players and business partners, followed by a restructuring in 1999.

Tzamal’s holding Company aims to focus on marketing via its companies: Tzamal Medical Industries Ltd (1985), Tzamal Jakobsohn Ltd (1999), Tzamal Bio-Pharma Ltd (2000), MP Vet Ltd ( 2002) and Tzamal 2B (2005).

Successful ExitsTzamal suppliers and strategic partners benefit from expert strategic representation in the Israeli market, often contributing significantly to profitable exits.

For example:

Boston Scientific acquired IVT for $345M in cash
Kyphone acquired Disc-O-Tech for $240M
Napro BioTherapeutics sold a comprehensive drug unit for $71.7M
Medtronic acquired CoreValve Inc., with an initial payment of $700M, followed by additional payments